Acquired resistance of EGFR-mutant lung cancer to AT790M-specificEGFR inhibitor: Emergenceofathird mutation (C797S) in the EGFR tyrosine kinase domain

JAMA Oncology

Volumn 1, Issue 7, 2015, Pages 982-984

  Yu, Helena A ^a,b   Tian, Shaozhou K ^a   Drilon, Alexander E ^a,b   Borsu, Laetitia ^a   Riely, Gregory J ^a,b   Arcila, Maria E ^a   Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADENOCARCINOMA; AGED; ANTAGONISTS AND INHIBITORS; CASE REPORT; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; DRUG SUBSTITUTION; ENZYMOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN TERTIARY STRUCTURE; TIME FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CLINICAL TRIALS, PHASE I AS TOPIC; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; DRUG SUBSTITUTION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84987849616     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1066     Document Type: Letter

References (6)

1. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240-2247.
2. Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009;462(7276):1070-1074.
3. Janne PA, Ramalingam SS, Yang JC-H, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC) [suppl; abstr 8009]. J Clin Oncol. 2014;32:5s.
4. Yu Z, Boggon TJ, Kobayashi S, et al. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res. 2007;67(21):10417-10427.
5. Schwartz PA, Kuzmic P, Solowiej J, et al. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc Natl Acad Sci U S A. 2014;111(1):173-178.
6. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286-2294.